• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5648
    • Acute Myelogenous Leukemia 202
    • Bladder Cancer 71
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 233
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 110
    • COVID-19 27
    • Gastrointestinal Cancer 93
    • General 320
    • Head and Neck Cancers 74
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 155
    • Kidney Cancer 376
    • Liver Cancer 25
    • Lymphoma 180
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 466
    • Myeloproliferative Disease 20
    • News 148
    • Non-Hodgkin Lymphoma 77
    • Non-Small Cell Lung Cancer 413
    • Other 256
    • Ovarian Cancer 43
    • Pancreatic Cancer 73
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 225
    • Sickle Cell 21
    • Small Cell Lung Cancer 72
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 3
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
    00:07:21

    Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

    Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups.

    262 Views
    2 years ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Trending

    Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
    0:05:57

    Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD

    Free
    92 Views
    1 year ago
    Cleveland Clinic
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Cancer Immunotherapy: how to predict results better
    00:00:35

    Cancer Immunotherapy: how to predict results better

    Free
    83 Views
    1 year ago
    Melwy
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    IMDC Classification Role in Treatment Decision-Making
    00:01:07

    IMDC Classification Role in Treatment Decision-Making

    Free
    149 Views
    1 year ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Clinical Trials on the Use of I-O and TKIs in RCC
    00:01:36

    Clinical Trials on the Use of I-O and TKIs in RCC

    Free
    33 Views
    1 year ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10

    Immunotherapy

    Geoffrey M. Lowman, PhD @thermofisher #Immunotherapy #Oncology #TCRSequencing #Cancer #Research Haplotype Analysis of the TCRB Locus by Long-amplicon TCRB Repertoire Sequencing Geoffrey M. Lowman, PhD @thermofisher #Immunotherapy #Oncology #TCRSequencing #Cancer #Research Haplotype Analysis of the TCRB Locus by Long-amplicon TCRB Repertoire Sequencing
    00:16:41

    Geoffrey M. Lowman, PhD @thermofisher #Immunotherapy #Oncology #TCRSequencing #Cancer #Research Haplotype Analysis of the TCRB Locus by Long-amplicon TCRB Repertoire Sequencing

    Free
    92 Views
    3 weeks ago
    cancernewsupdate
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
    00:09:38

    Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

    Free
    14 Views
    3 weeks ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Daniel Catenacci, MD @DocCatenacci @UChicagoMed #immunotherapy #cancer #research Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE Daniel Catenacci, MD @DocCatenacci @UChicagoMed #immunotherapy #cancer #research Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE
    00:10:32

    Daniel Catenacci, MD @DocCatenacci @UChicagoMed #immunotherapy #cancer #research Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE

    Free
    18 Views
    3 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jacob Adashek, DO @jacobadashek @USouthFlorida @MoffittNews @Dr_R_Kurzrock @AlexeyGoloubev #SITC20 #carcinomas Immunotherapy trials lack a biomarker for inclusion: implications for drug d... Jacob Adashek, DO @jacobadashek @USouthFlorida @MoffittNews @Dr_R_Kurzrock @AlexeyGoloubev #SITC20 #carcinomas Immunotherapy trials lack a biomarker for inclusion: implications for drug d...
    00:04:09

    Jacob Adashek, DO @jacobadashek @USouthFlorida @MoffittNews @Dr_R_Kurzrock @AlexeyGoloubev #SITC20 #carcinomas Immunotherapy trials lack a biomarker for inclusion: implications for drug d...

    Free
    44 Views
    3 months ago
    SITC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jennifer Baker Flechtner, Ph.D. @GenoceaBio #AACR #immunotherapy Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology Jennifer Baker Flechtner, Ph.D. @GenoceaBio #AACR #immunotherapy Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology
    0:13:55

    Jennifer Baker Flechtner, Ph.D. @GenoceaBio #AACR #immunotherapy Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology

    Free
    21 Views
    5 months ago
    AACR
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead
    0:06:09

    Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead

    Free
    31 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
    0:03:48

    Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.

    Free
    47 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jared Gollob @JaredGollob @KymeraTx #AACR20 What's the Advantage of IRAK4 Combined into One Molecule Jared Gollob @JaredGollob @KymeraTx #AACR20 What's the Advantage of IRAK4 Combined into One Molecule
    0:05:19

    Jared Gollob @JaredGollob @KymeraTx #AACR20 What's the Advantage of IRAK4 Combined into One Molecule

    Free
    11 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders
    0:05:17

    Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders

    Free
    27 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - In Closing - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - In Closing - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T
    0:01:30

    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - In Closing - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T

    Free
    18 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Will this affect clinicians - John Williams Ph.D. - City of Hope @cityofhope #cartcells #... Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Will this affect clinicians - John Williams Ph.D. - City of Hope @cityofhope #cartcells #...
    0:02:32

    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Will this affect clinicians - John Williams Ph.D. - City of Hope @cityofhope #cartcells #...

    Free
    18 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Common Questions - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Common Questions - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T
    0:01:52

    Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells - Common Questions - John Williams Ph.D. - City of Hope @cityofhope #cartcells #CAR-T

    Free
    16 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592